Effect of photodynamic therapy with two photosensitizers on Candida albicans

Azizi, Arash; Amirzadeh, Zohreh; Rezai, Maryam; Lawaf, Shirin; Rahimi, Arash

doi:10.1016/j.jphotobiol.2016.02.027

Cited by 42 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The extensive use of topical antifungal agents has led to an increased incidence of drug‐resistant strains such as fluconazole ‐ resistant Candida krusei to (Costa et al., ; de Souza et al., ; Lyon, Moreira, de Moraes, dos Santos, & de Resende, ). This has raised an urgent need to explore suitable alternative disinfection techniques, and antifungal PDT has shown significant efficacy in both in vitro and in vivo animal model studies (Azizi, Amirzadeh, Rezai, Lawaf, & Rahimi, ; Dai & Hamblin, ; Merigo et al., ; Pupo et al., ; Souza et al., ). A randomized clinical trial in 40 patients with denture stomatitis compared topical antifungal therapy, nystatin (1 × 10 5 IU four times daily for 15 days) versus PDT.…”

Section: Antimicrobial Photodynamic Therapy For Denture Stomatitismentioning

confidence: 99%

“…This has raised an urgent need to explore suitable alternative disinfection techniques, and antifungal PDT has shown significant efficacy in both in vitro and in vivo animal model studies (Azizi, Amirzadeh, Rezai, Lawaf, & Rahimi, 2016;Dai & Hamblin, 2017;Merigo et al, 2017;Pupo et al, 2011;Souza et al, 2010). A randomized clinical trial in 40 patients with denture stomatitis compared topical antifungal therapy, nystatin (1 × 10 5 IU four times daily for 15 days) versus PDT.…”

Section: Antimicrobial Photodynamic Therapy For Denture Stomatitismentioning

confidence: 99%

See 1 more Smart Citation

Learning from clinical phenotypes: Low‐dose biophotonics therapies in oral diseases

et al. 2018

View full text Add to dashboard Cite

This narrative review on the use of biophotonics therapies for management of oral diseases is written as a tribute to Prof. Crispian Scully. His seminal contributions to the field are highlighted by the detailed, comprehensive description of clinical presentations of oral diseases. This has enabled a more thorough, fundamental understanding of many of these pathologies by research from his group as well as inspired mechanistic investigations in many groups globally. In the same vein, a major emphasis of this narrative review is to focus on the evidence from human case reports rather than in vitro or in vivo animal studies that showcases the growing and broad impact of biophotonics therapies. The similarities and differences between two distinct forms of low-dose biophotonics treatments namely photodynamic therapy and photobiomodulation therapy are discussed. As evident in this review, a majority of these reports provide promising evidence for their clinical efficacy. However, a lack of adequate technical details, precise biological rationale, and limited outcome measures limits the current utility of these treatments. Future investigations should attempt to address these shortcomings and develop better designed, rigorous, controlled studies to fully harness the tremendous potential of low-dose biophotonics therapies.

show abstract

Section: Antimicrobial Photodynamic Therapy For Denture Stomatitismentioning

confidence: 99%

Section: Antimicrobial Photodynamic Therapy For Denture Stomatitismentioning

confidence: 99%

Learning from clinical phenotypes: Low‐dose biophotonics therapies in oral diseases

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Candida albicans is the most virulent Candida specie with a high economic and medical relevance due to high health care cost, in addition to high morbidity and mortality rates, especially in immunocompromised patients [ 30 ]. As a result, C. albicans is commonly used to test different materials as candidates for photosensitizers in PDT [ 31 – 32 ]. An FLG and Ce6 hybrid nanomaterial (FLG-Ce6) was used as the photosensitizer in combination with a red light-emitting diode (LED) array as the photoactivation light source.…”

Section: Introductionmentioning

confidence: 99%

A few-layer graphene/chlorin e6 hybrid nanomaterial and its application in photodynamic therapy against Candida albicans

Acosta

Moreno-Aguilar

Hernández-Sánchez³

et al. 2020

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

The global emergence of multidrug resistance of fungal infections and the decline in the discovery of new antibiotics are increasingly prevalent causes of hospital-acquired infections, among other major challenges in the global health care sector. There is an urgent need to develop noninvasive, nontoxic, and new antinosocomial approaches that work more effectively and faster than current antibiotics. In this work, we report on a biocompatible hybrid nanomaterial composed of few-layer graphene and chlorin e6 (FLG-Ce6) for the photodynamic treatment (PDT) of Candida albicans. We show that the FLG-Ce6 hybrid nanomaterial displays enhanced reactive oxygen species (ROS) generation compared with Ce6. The enhancement is up to 5-fold when irradiated for 15 min at 632 nm with a red light-emitting diode (LED). The viability of C. albicans in the presence of FLG-Ce6 was measured 48 h after photoactivation. An antifungal effect was observed only when the culture/FLG-Ce6 hybrid was exposed to the light source. C. albicans is rendered completely unviable after exposure to ROS generated by the excited FLG-Ce6 hybrid nanomaterial. An increased PDT effect was observed with the FLG-Ce6 hybrid nanomaterial by a significant reduction in the viability of C. albicans, by up to 95%. This is a marked improvement compared to Ce6 without FLG, which reduces the viability of C. albicans to only 10%. The antifungal action of the hybrid nanomaterial can be activated by a synergistic mechanism of energy transfer of the absorbed light from Ce6 to FLG. The novel FLG-Ce6 hybrid nanomaterial in combination with the red LED light irradiation can be used in the development of a wide range of antinosocomial devices and coatings.

show abstract

“…C. albicans has been shown to be susceptible to aPDT in their planktonic [53,54] and biofilms forms [54,55]. Moreover, this therapy appears to prevent the formation of biofilms by reducing their adhesion capacity [56].…”

Section: Introductionmentioning

confidence: 99%

Photodynamic Inactivation of Candida albicans in Blood Plasma and Whole Blood

Sousa

Gomes

Freitas³

et al. 2019

Antibiotics

View full text Add to dashboard Cite

The few approved disinfection techniques for blood derivatives promote damage in the blood components, representing risks for the transfusion receptor. Antimicrobial photodynamic therapy (aPDT) seems to be a promising approach for the photoinactivation of pathogens in blood, but only three photosensitizers (PSs) have been approved, methylene blue (MB) for plasma and riboflavin and amotosalen for plasma and platelets. In this study, the efficiency of the porphyrinic photosensitizer Tri-Py(+)-Me and of the porphyrinic formulation FORM was studied in the photoinactivation of Candida albicans in plasma and in whole blood and the results were compared to the ones obtained with the already approved PS MB. The results show that FORM and Tri-Py(+)-Me are promising PSs to inactivate C. albicans in plasma. Although in whole blood the inactivation rates obtained were higher than the ones obtained with MB, further improvements are required. None of these PSs had promoted hemolysis at the isotonic conditions when hemolysis was evaluated in whole blood and after the addition of treated plasma with these PSs to concentrates of red blood cells.

show abstract

Effect of photodynamic therapy with two photosensitizers on Candida albicans

Cited by 42 publications

References 39 publications

Learning from clinical phenotypes: Low‐dose biophotonics therapies in oral diseases

Learning from clinical phenotypes: Low‐dose biophotonics therapies in oral diseases

A few-layer graphene/chlorin e6 hybrid nanomaterial and its application in photodynamic therapy against Candida albicans

Photodynamic Inactivation of Candida albicans in Blood Plasma and Whole Blood

Contact Info

Product

Resources

About